Filters

Human Meningitis B neisserial heparin-binding antigen (MenB NHBA) antibody positive control serum

Human Meningitis B neisserial heparin-binding antigen (MenB NHBA) antibody positive control serum size: 1 mL 260

Supplier ADI
Price 260
Size 1 mL
ELISA kit stock availabilityAvailable In Stock
ELISA's descriptionHuman Meningitis B neisserial heparin-binding antigen (MenB NHBA) antibody positive control serum
CategoryControl Serum
S typen/a
Antibody's host issee techfile
PurificationAffinity purified
Description Azide Free Serum for cell culture FBS fetal bovine serum, Filtered serum for sterility, Isotype or positive controls by peptides, Plasmas on request, Serum includes all , The polyclonal serum contains no red or white blood cells or , and any , antibodies and deactivated samples, it is the blood plasma ,  ,  ,  , (coagulation) and all the , Antigens are peptides or recombinant or native dependent on the production method, and antibodies not used in , and , antibodies, antigens, blood clotting , clotting factors, electrolytes, exogenous , fibrinogens, hormones, microorganisms, not including the , proteins , substances like drugs 
Properties Depending on the epitopes used human ELISA kits can be cross reactive to many other species, Mainly analyzed are human serum, Modern , cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies, human cell culture supernatants and biological samples, plasma, primarily , saliva, urine,  , (Homo sapiens, Homo sapiens sapiens), Human proteins, humans , ssp
AboutC, Serum should be stored at +5°
French translationanticorps
Gene targetMeningitis B neisserial heparin-binding (MenB NHBA)
Short nameMeningitis B neisserial heparin-binding antigen (MenB NHBA) antibody positive control serum
Technique antigenes, antigen
Species Humans, Human
Alternative name sapiens Meningitis B neisserial heparin-binding protein (MenB NHBA) (Antibody to) positive reference blood serum, H
Alternative techniqueantigenes

Subscribe to our Newsletter